Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial

Eli Lilly said orforglipron was better at lowering blood sugar levels than Novo Nordisk’s oral semaglutide, and helped patients lose more weight.